WHO and Medicines Patent Pool announced agreement with NIH for COVID-19 health technologies
On May 12, 2022, WHOï¾’s COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement…
Cepheid received Emergency Use Authorization for Xpertï¾® Xpress CoV-2 plus
On May 12, 2022, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
NIH licensed COVID-19 research tools and early-stage technologies to WHO program
On May 12, 2022, the U.S. National Institutes of Health announced that it had licensed 11 COVID-19 research…
Lucira filed for authorization of first-of-its-Kind COVID-19 & flu at-home molecular test
On May 11, 2022, Lucira Health announced that it had submitted a request to the U.S. Food and…
Biotechnology | COVID-19 | Infectious Disease | Life Science News | Non-Profit Research | Therapeutics
KPWHRI report supported value of COVID-19 drugs
On May 11, 2022, Kaiser Permanente Washington Health Research Institute reported that new treatments for people at high…
Lucira received CE Mark for both COVID-19 & flu and COVID-19 molecular tests
On May 9, 2022, Lucira Health announced that both its COVID-19 & Flu and COVID-19 molecular tests have…
Novavax submitted variations to expand Australian and New Zealand provisional approval of Nuvaxovid COVID-19 vaccine in Great Britain
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
Novavax’s COVID-19 vaccine Nuvaxovid arrived in Singapore
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
WHO reported 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021
On May 5, 2022, the World Health Organization (WHO) reported estimates that show the full death toll associated…
Moderna filed to expand conditional Marketing Authorization for COVID-19 vaccine to include children six months to under six years in the EU
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
Moderna filed for authorization of Its COVID-19 vaccine in young children six months to under six years of age
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
Biotechnology | COVID-19 | FDA | Life Science News | Vaccine
Pfizer and BioNTech submitted application for U.S. EUA for COVID-19 vaccine booster dose in children 5 through 11 years of age
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
Vekluryï¾® (Remdesivir) was first and only approved treatment for pediatric patients under 12 years of age with COVID-19
On Apr. 25, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) had approved a…
Novavax announced initiation of COVID-19 vaccine booster study in adolescents in phase 3 PREVENT-19 trial
On Apr. 22, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
WHO recommended Paxlovid for high-risk COVID patients
On Apr. 22, 2022, the World Health Organization (WHO) made a strong recommendation for nirmatrelvir and ritonavir, sold…
Cocrystal Pharma collaborated with the NIAID to evaluate COVID-19 protease inhibitors
On Apr. 21, 2022, Cocrystal Pharma announced a Non-Clinical Evaluation Agreement with the National Institute of Allergy and…
CureVac and GSKï¾’s bivalent second-generation mRNA accine candidate shown to be highly effective against SARS-CoV-2 variants
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…
Initial results from Novavax’ COVID-19-Influenza vaccine trial were first to show feasibility of combination vaccine
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
Tonix Pharm announced results of retrospective observational database study in over 50,000 long COVID patients
On Apr. 20, 2022, Tonix Pharmaceuticals announced the results of a retrospective observational database study in over 50,000…
Novavax announced approval of Nuvaxovid COVID-19 vaccine for primary and booster immunization in Japan
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
Moderna announced clinical update on bivalent COVID-19 booster platform
On Apr. 19, 2022, Moderna announced new clinical data on its bivalent COVID-19 booster platform including data on…
COVID-19 booster effectiveness remained high during Omicron surge
On Apr. 18, 2022, the Military Health System reported that active-duty service members who received a COVID-19 vaccine…
Pfizer and BioNTech data demonstrated high immune response following booster dose of COVID-19 vaccine in children 5 through 11 years of age
On Mar. 14, 2022, Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the…
Regeneron antibody cocktail approved by European Commission to treat and prevent COVID-19
On Nov. 12, 2021, Regeneron announced that the U.S. Food and Drug Administration had extended by three months…
FDA authorized first COVID-19 diagnostic test using breath samples
On Apr. 14, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
Veruï¾’s novel COVID-19 drug candidate reduced deaths by 55% in hospitalized patients in interim analysis of phase 3 study
On Apr. 11, 2022, Veru announced positive efficacy and safety results from a planned interim analysis of the…
Novavax and Serum Institute of India received EUA for COVID-19 vaccine in Thailand
On Apr. 8, 2022, Novavax announced and Serum Institute of India (SII), the world’s largest vaccine manufacturer by…
IAVI and Moderna partnered to tackle broad global health priorities using mRNA for vaccines and antibodies
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO(molnupiravir), an investigational oral antiviral COVID-19…